Lauren Sahakian1, Rhiannon T Filippone1, Rhian Stavely1,2, Ainsley M Robinson1, Xu Sean Yan1, Raquel Abalo3,4, Rajaraman Eri5, Joel C Bornstein6, Mark R Kelley7, Kulmira Nurgali1,8,9. 1. Institute for Health and Sport, Victoria University; Western Centre for Health, Research and Education, Sunshine Hospital, Melbourne, Victoria, Australia. 2. Department of Pediatric Surgery, Pediatric Surgery Research Laboratories, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA. 3. Área de Farmacología y Nutrición y Unidad Asociada al Instituto de Química Médica (IQM) del Consejo Superior de Investigaciones Científicas (CSIC), Universidad Rey Juan Carlos (URJC), Alcorcón, Madrid, Spain. 4. High Performance Research Group in Physiopathology and Pharmacology of the Digestive System at URJC, Alcorcón, Madrid, Spain. 5. University of Tasmania, School of Health Sciences, Launceston, Tasmania, Australia. 6. Department of Physiology, Melbourne University, Melbourne, Australia. 7. Indiana University Simon Comprehensive Cancer Center, Departments of Pediatrics, Biochemistry & Molecular Biology and Pharmacology & Toxicology, Program in Pediatric Molecular Oncology & Experimental Therapeutics, Herman B Wells Center for Pediatric Research, Indiana University School of Medicine Indianapolis, USA. 8. Department of Medicine Western Health, Faculty of Medicine, Dentistry and Health Sciences, The University of Melbourne, Melbourne, Victoria, Australia. 9. Regenerative Medicine and Stem Cells Program, Australian Institute of Musculoskeletal Science (AIMSS), Melbourne, Victoria, Australia.
Abstract
BACKGROUND: Inflammatory bowel disease (IBD) associates with damage to the enteric nervous system (ENS), leading to gastrointestinal (GI) dysfunction. Oxidative stress is important for the pathophysiology of inflammation-induced enteric neuropathy and GI dysfunction. Apurinic/apyrimidinic endonuclease 1/redox factor-1 (APE1/Ref-1) is a dual functioning protein that is an essential regulator of the cellular response to oxidative stress. In this study, we aimed to determine whether an APE1/Ref-1 redox domain inhibitor, APX3330, alleviates inflammation-induced oxidative stress that leads to enteric neuropathy in the Winnie murine model of spontaneous chronic colitis. METHODS: Winnie mice received APX3330 or vehicle via intraperitoneal injections over 2 weeks and were compared with C57BL/6 controls. In vivo disease activity and GI transit were evaluated. Ex vivo experiments were performed to assess functional parameters of colonic motility, immune cell infiltration, and changes to the ENS. RESULTS: Targeting APE1/Ref-1 redox activity with APX3330 improved disease severity, reduced immune cell infiltration, restored GI function ,and provided neuroprotective effects to the enteric nervous system. Inhibition of APE1/Ref-1 redox signaling leading to reduced mitochondrial superoxide production, oxidative DNA damage, and translocation of high mobility group box 1 protein (HMGB1) was involved in neuroprotective effects of APX3330 in enteric neurons. CONCLUSIONS: This study is the first to investigate inhibition of APE1/Ref-1's redox activity via APX3330 in an animal model of chronic intestinal inflammation. Inhibition of the redox function of APE1/Ref-1 is a novel strategy that might lead to a possible application of APX3330 for the treatment of IBD.
BACKGROUND: Inflammatory bowel disease (IBD) associates with damage to the enteric nervous system (ENS), leading to gastrointestinal (GI) dysfunction. Oxidative stress is important for the pathophysiology of inflammation-induced enteric neuropathy and GI dysfunction. Apurinic/apyrimidinic endonuclease 1/redox factor-1 (APE1/Ref-1) is a dual functioning protein that is an essential regulator of the cellular response to oxidative stress. In this study, we aimed to determine whether an APE1/Ref-1 redox domain inhibitor, APX3330, alleviates inflammation-induced oxidative stress that leads to enteric neuropathy in the Winnie murine model of spontaneous chronic colitis. METHODS: Winnie mice received APX3330 or vehicle via intraperitoneal injections over 2 weeks and were compared with C57BL/6 controls. In vivo disease activity and GI transit were evaluated. Ex vivo experiments were performed to assess functional parameters of colonic motility, immune cell infiltration, and changes to the ENS. RESULTS: Targeting APE1/Ref-1 redox activity with APX3330 improved disease severity, reduced immune cell infiltration, restored GI function ,and provided neuroprotective effects to the enteric nervous system. Inhibition of APE1/Ref-1 redox signaling leading to reduced mitochondrial superoxide production, oxidative DNA damage, and translocation of high mobility group box 1 protein (HMGB1) was involved in neuroprotective effects of APX3330 in enteric neurons. CONCLUSIONS: This study is the first to investigate inhibition of APE1/Ref-1's redox activity via APX3330 in an animal model of chronic intestinal inflammation. Inhibition of the redox function of APE1/Ref-1 is a novel strategy that might lead to a possible application of APX3330 for the treatment of IBD.
Authors: A Cornet; T C Savidge; J Cabarrocas; W L Deng; J F Colombel; H Lassmann; P Desreumaux; R S Liblau Journal: Proc Natl Acad Sci U S A Date: 2001-10-30 Impact factor: 11.205
Authors: A M Haase; T Gregersen; L A Christensen; J Agnholt; J F Dahlerup; V Schlageter; K Krogh Journal: Neurogastroenterol Motil Date: 2016-01-04 Impact factor: 3.598
Authors: Jane A Roberts; Leonie Durnin; Keith A Sharkey; Violeta N Mutafova-Yambolieva; Gary M Mawe Journal: J Physiol Date: 2013-06-03 Impact factor: 5.182
Authors: Benoit Chassaing; Gayathri Srinivasan; Maria A Delgado; Andrew N Young; Andrew T Gewirtz; Matam Vijay-Kumar Journal: PLoS One Date: 2012-09-05 Impact factor: 3.240
Authors: Mahmut Mijit; Randall Wireman; Lee Armstrong; Silpa Gampala; Zonera Hassan; Christian Schneeweis; Guenter Schneider; Chi Zhang; Melissa L Fishel; Mark R Kelley Journal: Front Oncol Date: 2022-03-24 Impact factor: 6.244
Authors: Rhiannon T Filippone; Narges Dargahi; Rajaraman Eri; Jose A Uranga; Joel C Bornstein; Vasso Apostolopoulos; Kulmira Nurgali Journal: Int J Mol Sci Date: 2022-07-14 Impact factor: 6.208
Authors: Rachel A Caston; Silpa Gampala; Lee Armstrong; Richard A Messmann; Melissa L Fishel; Mark R Kelley Journal: Drug Discov Today Date: 2020-10-24 Impact factor: 7.851
Authors: Curtis Heisel; Jonah Yousif; Mahmut Mijiti; Kostas Charizanis; Mitchel Brigell; Timothy W Corson; Mark R Kelley Journal: J Cell Signal Date: 2021